US 12,264,335 B2
Natural killer cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof
Dario Campana, Singapore (SG); David Shook, Memphis, TN (US); and Masaru Imamura, Chuo-ku (JP)
Assigned to National University of Singapore, Singapore (SG); and St. Jude Children's Research Hospital, Inc., Tennessee (TN)
Filed by National University of Singapore, Singapore (SG); and St. Jude Children's Research Hospital, Inc., Memphis, TN (US)
Filed on Dec. 16, 2022, as Appl. No. 18/067,199.
Application 16/550,548 is a division of application No. 15/309,362, granted, now 10,428,305, issued on Oct. 1, 2019, previously published as PCT/SG2015/050111, filed on May 14, 2015.
Application 18/067,199 is a continuation of application No. 16/986,742, filed on Aug. 6, 2020, granted, now 11,560,548.
Application 16/986,742 is a continuation of application No. 16/550,548, filed on Aug. 26, 2019, granted, now 10,774,311, issued on Sep. 15, 2020.
Claims priority of provisional application 61/993,494, filed on May 15, 2014.
Prior Publication US 2023/0220343 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/54 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/16 (2006.01); C12N 15/62 (2006.01)
CPC C12N 5/0646 (2013.01) [A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 39/4613 (2023.05); A61K 39/4644 (2023.05); C07K 14/5443 (2013.01); C07K 14/70517 (2013.01); C12N 5/0006 (2013.01); C12N 15/62 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/03 (2013.01); C12N 2501/2315 (2013.01); C12N 2510/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A population of natural killer (NK) cells that express all or a functional portion of interleukin-15 (IL-15), wherein the all or a functional portion of the IL-15 is fused to all or a portion of a transmembrane protein that anchors the expressed IL-15 as a cell membrane-bound polypeptide (mbIL15) of the NK cells.